State of Alaska Department of Revenue grew its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 1.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,680 shares of the biopharmaceutical company’s stock after purchasing an additional 75 shares during the period. State of Alaska Department of Revenue’s holdings in SAGE Therapeutics were worth $903,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Dimensional Fund Advisors LP increased its holdings in shares of SAGE Therapeutics by 40.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 109,054 shares of the biopharmaceutical company’s stock valued at $10,441,000 after acquiring an additional 31,571 shares during the last quarter. RTW Investments LP acquired a new position in shares of SAGE Therapeutics during the 4th quarter valued at about $15,900,000. California Public Employees Retirement System increased its holdings in shares of SAGE Therapeutics by 3.4% during the 4th quarter. California Public Employees Retirement System now owns 62,600 shares of the biopharmaceutical company’s stock valued at $5,996,000 after acquiring an additional 2,055 shares during the last quarter. Partner Investment Management L.P. acquired a new position in shares of SAGE Therapeutics during the 4th quarter valued at about $592,000. Finally, Mackenzie Financial Corp increased its holdings in shares of SAGE Therapeutics by 9.5% during the 3rd quarter. Mackenzie Financial Corp now owns 17,175 shares of the biopharmaceutical company’s stock valued at $2,426,000 after acquiring an additional 1,486 shares during the last quarter.

Shares of NASDAQ:SAGE opened at $164.73 on Monday. SAGE Therapeutics Inc has a twelve month low of $79.88 and a twelve month high of $177.14. The company has a market cap of $7.76 billion, a P/E ratio of -20.39 and a beta of 2.91.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.89) by ($0.49). The business had revenue of $0.27 million during the quarter. During the same period in the prior year, the company posted ($1.75) earnings per share. On average, equities analysts forecast that SAGE Therapeutics Inc will post -12.58 earnings per share for the current year.

In other SAGE Therapeutics news, Director Steven M. Paul sold 1,543 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $161.62, for a total value of $249,379.66. Following the completion of the sale, the director now owns 272,777 shares in the company, valued at approximately $44,086,218.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven M. Paul sold 3,775 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $161.05, for a total value of $607,963.75. Following the completion of the sale, the director now owns 272,777 shares of the company’s stock, valued at approximately $43,930,735.85. The disclosure for this sale can be found here. Insiders sold a total of 175,811 shares of company stock valued at $27,771,729 in the last quarter. Corporate insiders own 5.10% of the company’s stock.

Several brokerages recently weighed in on SAGE. BidaskClub upgraded SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. ValuEngine downgraded SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Guggenheim began coverage on SAGE Therapeutics in a research note on Friday, February 22nd. They set a “buy” rating and a $205.00 target price for the company. One research analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $201.45.

ILLEGAL ACTIVITY NOTICE: “State of Alaska Department of Revenue Raises Holdings in SAGE Therapeutics Inc (SAGE)” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/state-of-alaska-department-of-revenue-raises-holdings-in-sage-therapeutics-inc-sage/2980822.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders.

Featured Article: What is dollar cost averaging (DCA)?

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.